Margaret Johnson, APRN
Nurse Practitioner · West Columbia, SCNPI 1750535530
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,105 of the $15,198 with a category attached, or 66.5%. Alkermes, Inc. accounts for 75.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $7,017 and has fallen 95.1% since, to $343 in 2025. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $44.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$12K
- Neurocrine Biosciences, Inc.$734
- Johnson & Johnson$692
- Teva Pharmaceuticals USA, Inc.$574
- Otsuka America Pharmaceutical, Inc.$517
- AbbVie$447
- plus $730 from 7 others
What the payments were for
- Speaking & faculty fees$10,10566%
- Food & beverage$5,08333%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 58 | $11,505 |
| Neurocrine Biosciences, Inc. | 56 | $734 |
| Johnson & Johnson | 38 | $692 |
| Teva Pharmaceuticals USA, Inc. | 62 | $574 |
| Otsuka America Pharmaceutical, Inc. | 39 | $517 |
| AbbVie | 48 | $447 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $276 |
| E.r. Squibb & Sons, L.L.C. | 5 | $147 |
| Sunovion Pharmaceuticals Inc. | 8 | $106 |
| Indivior Inc. | 6 | $81 |
| Vanda Pharmaceuticals Inc. | 4 | $60 |
| Lundbeck LLC | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$40,900
- ARISTADA INITIO$10,225
- LYBALVI$488
- INVEGA SUSTENNA$111
How this compares
$15,198 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 107 | $342,492 |
| AristadaAripiprazole Lauroxil | 53 | $183,428 |
| Abilify MaintenaAripiprazole | 56 | $162,035 |
| IngrezzaValbenazine Tosylate | 12 | $102,199 |
| Invega TrinzaPaliperidone Palmitate | 11 | $82,329 |
| FanaptIloperidone | 11 | $45,028 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $21,585 |
| Haloperidol Decanoate | 51 | $3,563 |
| Fluphenazine Decanoate | 25 | $2,994 |
| Clozapine | 30 | $2,215 |
| Aripiprazole | 51 | $1,764 |
| Paliperidone ErPaliperidone | 16 | $1,717 |
| Quetiapine Fumarate | 50 | $1,581 |
| Benztropine Mesylate | 77 | $1,183 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 17 | $1,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $692 | $424,821118 claims |
| Alkermes, Inc.Aristada, Lybalvi | $11,505 | $205,01366 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $517 | $162,03556 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $734 | $102,19912 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $60 | $45,02811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in West Columbia
- Janice MorrowWest Columbia$13K
- Merritt StevensonWest Columbia$8K
- Mallory AndersonWest Columbia$7K
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.